
InterLeukin Combinatorial Therapies
Interleukin Combinatorial Therapies is developing the next generation of cancer-selective interleukin (cytokine)-based therapeutics. Through a process called “bystander antitumor activity” their unique engineered therapeutic cytokines destabilize cancer cells, resulting in direct killing or indirect toxicity through activation of the immune system and inhibition of angiogenesis.